Novocure (NASDAQ: NVCR) announced that the National Comprehensive Cancer Network (NCCN) has recommended Optune as a standard treatment option for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE